TC Biopharm (Holdings) Plc (TCBP)
TC Biopharm (Holdings) Plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Motherwell, GB. The stock last traded at $0.50, up 0.00% on the session, giving a market capitalisation of $256,496. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 0.01 implies it has historically moved less than the broad market.
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.
TC Biopharm (Holdings) Plc is most often compared with the following Healthcare names: